CHU of Liege, Nuclear Medicine and Oncological Imaging Division, Medical Physics Department, Liege, Belgium.
CHU of Liege, Department of Clinical Hematology, Liege, Belgium.
Contrast Media Mol Imaging. 2017 Jul 27;2017:6162845. doi: 10.1155/2017/6162845. eCollection 2017.
An observational study was set up to assess the feasibility of [F]FPRGD PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [F]NaF/[F]FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of [F]FPRGD. The obtained images were compared with results of low dose CT and already available results of a combined [F]NaF/[F]FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [F]FPRGD PET/CT compared to low dose CT (98%) or [F]NaF/[F]FDG PET/CT (70%) and all FLs detected with [F]FPRGD PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [F]FPRGD positive lesions were seen than [F]NaF/[F]FDG positive lesions. This study suggests that [F]FPRGD PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with [F]FPRGD uptake were already detected with CT alone.
一项观察性研究旨在评估 [F]FPRGD PET/CT 对多发性骨髓瘤 (MM) 患者成像的可行性，并比较其与单独低剂量 CT 以及联合 [F]NaF/[F]FDG PET/CT 图像的检测率。共纳入 4 例患者（2 例初诊患者和 2 例复发 MM 患者），在注射 [F]FPRGD 后行全身 PET/CT。将获得的图像与低剂量 CT 结果和已经获得的联合 [F]NaF/[F]FDG PET/CT 结果进行比较。共检测到 81 个局灶性病变 (FL)，其中 72 个 (89%) 或 8 个 (10%) FL 分别伴有骨破坏或骨折。与低剂量 CT（98%）或 [F]NaF/[F]FDG PET/CT（70%）相比，[F]FPRGD PET/CT 检测到的 FL 较少（54%），且所有用 [F]FPRGD PET 检测到的 FL 均与骨病变有关。在一名初诊患者中，[F]FPRGD 阳性病变比 [F]NaF/[F]FDG 阳性病变多。这项研究表明，[F]FPRGD PET/CT 在检测晚期疾病患者的骨髓瘤病变方面可能用处不大，因为所有摄取 [F]FPRGD 的 FL 均已通过单独 CT 检测到。
